Investor and Scientific Conference aside, I am not sure why some feels Missling should spent more time and effort promoting Anavex.
Promotion would be called out as Pumping right? Pumping may have short term effect perhaps lowing cost of dilution, but to me seems short lived and likely to cause more trouble than good.
Not Pumping is called out as letting down investors - "do something Missling I've not got rich quick!", Or
"I've lost money having made my own choice of investing in $AVXL."
Perhaps investing too early and not learning that biotech takes time that can gainfully used with skill to trade the volatility.
"Worst stock ever and now I want to blame someone else."
It will all come out in the wash with positive controlled trial readouts and is all that in the end counts.
So far it seems things are going in the right direction...
News 
Market Data 
Discover 
